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Abstract
Background: Deficiencies of the complement-
regulatory proteins on RBC (RBCMal) of patients with
Plasmodium falciparum were reported. Here, we
sought to determine the role of affinity-purified C-
reactive protein from patients (CRPMal), in modulating
the complement-regulatory proteins and downstream
effect on complement-cascade. Methods: CRPMal was
characterized by analytical ultracentrifuge and
electrophoretic analysis. Surface plasmon resonance,
Western blotting, co-immuno-precipitation, flow-
cytometry and ELISA determined the binding of CRPMal
with RBCMal. Modifications of membranes for RBCMal-
CRPMal binding were explored by scanning electron
microscopy, osmotic and turbulence fragility,
hydrophobicity and oxyhemoglobin release. Flow-
cytometry, ELISA, Western blotting and Scatchard
analysis monitored the status of complement-
regulatory proteins on RBCMal. Complement-activation
via CRPMal was quantified by C3-deposition and
hemolysis. Results: CRPMal binds specifically to RBCMal
through distinct molecules. Such binding altered the
normal discoid-shape of RBCMal with increased
membrane fluidity and hydrophobicity. In the presence
of CRP, RBCMal showed reduced complement-
regulatory proteins (CR1 or CD35, CD55 and CD59)
with decreased affinity. These changes caused
enhanced C3-deposition and complement-mediated
hemolysis. Conclusion: Taken together, we have
established the contributory effect of CRPMal causing
decreased complement-regulatory proteins, possibly
providing a new mechanism of complement-fueled
RBCMal destruction refractory to erythrophagocytosis
and may account for pathogenesis of anemia.
Introduction
Malaria incidence ranged between 2-2.5 million
cases annually in India [http://www.whoindia.org/EN/
Section3/Section128/Section235.htm]. Despite a few
reports [1-3], the pathology of Plasmodium falciparum
(Pf) anemia remains to be defined. Complement-
regulatory proteins on RBC include complement receptor
1 (CR1 or CD35), decay accelerating factor (DAF or
CD55), and the membrane inhibitor of reactive lysis
(CD59). CR1 promotes the inactivation and binding of
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C3b in immune complexes (ICs). CR1 and CD55
accelerate the degradation of C3b convertases and CD59
interfere with the assembly of the membrane attack
complex C5b-9 [4-5]. Plasmodium falciparum exploits
CR1 as an adhesion-ligand in the process of rosetting,
the pathogenic clumping of erythrocytes [6]. Destruction
of erythrocytes, however, cannot be solely explained by
the direct effect of the parasite [7-8], or by deposition of
parasite-derived antigen nor by its surface damage through
IgG and complement-regulatory proteins or complement-
fixation [9-10] or alternatively C3b-bearing ICs via CR1
reticulo-endothelial system [11-12].
C-reactive protein (CRP), an acute-phase reactant,
is found in trace amounts in normal human serum (NHS)
[13], markedly increased in inflammatory conditions [14-
15]. Our laboratory convincingly demonstrated
glycosylated molecular variants of human CRP induced
in certain pathological conditions [16], which interact with
several biological macromolecules [17-18]. CRP elicits a
multitude of effects on different blood cells and can
activate the complement-cascade by binding with
phosphocholine (PC) containing substances [19-21].
Excess ICs in vasculature may deposit in tissues and
complement is required in removing them. This evidence
led us to examine the composite role of CRP and
complement regulatory proteins in the pathogenesis of
Pf anemia.
Accordingly, CRPMal was affinity-purified and
characterized from the serum of freshly recruited new
cohort of malaria patients. The specific-binding of CRPMal
with RBCMal was demonstrated which altered the
membrane characteristics resulting in the significant
decrease of membrane-anchored CR1, CD55 and CD59
on RBCMal. This RBC-CRPMal complex leads to
concomitant C3b-deposition on RBCs and its subsequent
clearance from circulation through hemolysis. Our
findings, for the first time, suggest a possible new
mechanism in which RBC-CRP complex, being triggered
with complement, promote the destruction and clearance
of damaged RBCs in malaria.
Materials and Methods
Study design
Clinically confirmed individuals (mean age 35.14 ± 15.7
years, n=65) infected with asexual Plasmodium falciparum and
age-matched normal healthy volunteers (n=45) were enrolled.
The diagnosis was established on the basis of microscopic
examination of Giemsa-stained thick and thin blood smears,
DAT test, concurrent axillary temperature ≥37°C, headache,
fever, vomiting, painful joints and shaking chills with a
hemoglobin concentration of 4.5-7.8 g/dl. Individuals had no
history of red cell disorder, autoimmune diseases and parasitic
co-infections. The Institutional Human Ethical Committee had
approved the study, and samples were taken with the consent
of the donors, patients.
Clinical samples
Blood were collected in Alsever’s solution and used within 2-4
hours. It was centrifuged, buffy coat removed. Washed RBC
were suspended in Tris/HCl (20 mM)-NaCl (150 mM) (TBS, pH
7.5) containing 1% BSA (TBS-BSA) and used immediately. The
RBCMal consisting of a mixture of infected (7.2-8.6 parasitemia/
red cell) and uninfected (~90%) population were used for all
the experiments. Fresh sera from patients (MS) and normal were
obtained by clotting blood samples.
Purification and characterization of human CRPMal
Serum showing elevated levels of CRP by latex
agglutination (Rhelax-CRP kit, Tulip, India) was selected for
purification [16, 22]. Typically, serum samples from individual
patients (n=10) were separately passed through an agarose
column in Tris/HCl (50 mM) buffered saline (TBS, pH 7.5)-
Ca+2(5.0 mM). It was immediately applied to a Sepharose-PC
matrix, washed with TBS-Ca+2 (10 mM) and bound protein was
eluted with EDTA (10 mM)-Ca+2 (1.0 mM). Protein fractions were
further purified through another Sepharose–PC column using
TBS-Ca+2 (10 mM) and pure CRP was eluted with PC (2.0 mM)
in TBS-Ca+2 (0.50 mM). The eluted protein was dialyzed against
20 mM Hepes with saline containing EDTA (2.0 mM), followed
by same buffer without EDTA. The protein was estimated using
the extinction coefficient, E1%1cm at 280 nm of 19.50 [23] and also
by Lowry method [24]. The yield of purified CRPMal was 105-139
µg/ml corresponded to 210-278-fold induced above the normal
level (0.5 µg/ml) confirming that CRPMal as an acute-phase protein
[14]. A single band in SDS-PAGE [25], autoradiograph of
125ICRPMal (Fig.1A) and analytical isoelectric focusing with a pI
of 8.4 confirmed its purity (Fig.1B) [26]. CRP was >99% pure
based on the reactivity with anti-human CRP and no binding
with anti-human IgG antibodies in Western blotting [18, 27]. A
commercially available CRP from Tulip (CRPTulip), purified from
pooled human plasma, was used as control and showed similar
subunit molecular weight like normal CRP (CRPN) (23 kDa, Fig.
1A) [28]. However, the subunit molecular weight of CRPMal was
different (27 kDa, Fig. 1A) [16-18]. A small change between
these two CRPs confirmed the induction of disease-associated
molecular variant. CRPTulip behaved differently than CRPMal. A
homology to known human CRP sequences [29] suggested
similar native pentraxin structures of CRPMal and CRPTulip.
The homogeneity of CRPMal was additionally confirmed
by analyzing sedimentation velocity experiment (Fig. 1C). CRPMal
with an absorbance 0.1-0.5 at 280 nm were loaded on a Beckman
XL-A ultracentrifuge in an An60Ti rotor at 20°C at 4000 rpm
along with buffer in reference compartment into 2-sector cells.
Radial absorbance data were acquired at 280 nm in continuous
mode for every 5 min for a period of 10 h with radial increments
of 0.002 cm. Data were analyzed with SEDFIT using the C(S) or
C(M) Lamm equation model [30-32]. Collections of 10-30 radial
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scans were used for analysis and 200 sedimentation coefficients
between 1.2 and 20 S were employed for calculation. The
position of the meniscus and cell bottom were determined and
refined in the final fit. Analysis resulted in high-quality-data
fits (Fig. 1Ci) with randomly distributed residuals and root-
mean-square deviations below 0.1% (Fig. 1Cii). The calculated
sedimentation coefficient distributions revealed well-resolved
peaks corresponding to the different aggregation states of the
CRP (Fig. 1Ciii). Pentameric CRPMal appears to be the major
macroscopic form (75%) with a peak at 7.5S, whereas by
intermolecular association, the solution also contained the
decameric (9.8S) form, whose share hardly reached 15% (Fig.
1Civ). Depending on conditions of microenvironments, CRP
may exist as monomer, pentamer or multimer each of them
showing preferential ligand binding with differential biological
relevance [33].
Examination of RBC-CRP binding
CRPMal or CRPTulip, at physiological concentration (10 µg/
ml) was incubated in TBS-Ca+2 (2.0 mM, pH 7.5)-PC (1.0 mM);
designated as CRP-PC-Ca+2-complex and used for following
experiments. Membranes were prepared by re-suspending
packed RBCs in ice-cold buffer containing digitonin (1.0 mg/
ml) for 20 mins (0°C) [34], centrifuged and washed ghosts were
solubilized in equal volume of extraction buffer (20 mM Tris-
HCl, pH 7.5; 1.0%Triton X-100; 0.1% SDS; 200 mM NaCl) for 1
h at 0°C and centrifuged. The supernatant containing membrane
proteins was quantified [24].
Surface plasmon resonance (SPR)
SPR analysis of the interaction between CRPMal and RBCMal
membrane proteins was performed using a BIACORE 3000
instrument. CRPMal (0.5-10 µg/ml) in sodium acetate buffer
(10 mM, pH 4.5) was immobilized onto the carboxymethylated
dextran surface of a CM5 sensor chip. All flow cells of CM5
were activated at 25°C, each with a mixture (20 µl) of 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (0.20 M) and N-hydroxy-
sulfosuccinimide (0.05 M) at a flow rate 5 µl/min, subsequently
CRPMal was injected. Unreacted groups were blocked with
ethanolamine (20 µl, 1 M, pH 8.5). Flow buffer was Hepes
(10 mM)-NaCl (150 mM)-Ca+2 (2 mM)-PC (1.0 mM)-Tween-20
(0.005 %), pH 7.4. Activated and blocked flow cell served as
blank sensograms for substraction of the bulk refractive index
background. The sample was first injected over the negative
control surface and then over immobilized CRP. RBC membrane
(5-50 µg/ml) were passed at a flow rate of 30 µl/min. Association
and dissociation times were 5 and 3 min respectively and the
regeneration consisted of a 30 µl injection of 2 M NaCl.
Sensograms were analyzed with the Biaevaluation software
version 4.1. Resonance responses in arbitrary units (RU) were
plotted against the varying concentrations of RBC membrane
protein and the slopes of the linear plots were calculated. Such
analysis with RBCN membrane proteins was performed for
comparison.
Analysis of membrane alterations induced on RBC due
to binding with CRP
RBCMal or RBCN (1x 109 cells/tube, n = 15) were incubated
with CRPMal-PC-Ca+2 complex for 1 h on ice and washed with
TBS-Ca+2 and following experiments were done [35-36].
A) Osmofragility assay. RBC-CRPMal-PC-Ca+2 complex was
exposed to different NaCl concentrations for another 1 h at
37°C. Only cells in TBS-Ca+2 served as control. Lysis of RBC in
distilled water was taken as 100%. The hemolysis (%), as a
measure of osmotic fragility was analyzed spectro-
photometrically before and after binding with CRPMal.
Hemolysis (%) = OD412 nm at particular saline
concentration/ OD412 nm with distilled water X 100.
Fig. 1. Characterization of affinity-purified CRPMal:
A. Electrophoresis. Equal amounts of affinity-
purified CRPMal (1 µg, lane 1) was electrophoretically
analyzed on a SDS-PAGE (10%) and silver stained.
A commercially available CRPTulip was used as normal
CRP (lane 2). Lane 3 is autoradiograph of 125ICRPMal.
B. Isoelectric focusing. CRPMal (1.5 µg) was applied
to ampholine polyacrylamide tube gel (4%) in a pH
gradient (3.5-10.0) and stained with silver nitrate. C.
Sedimentation velocity analysis. (i). Optical traces
of CRPMal during ultracentrifugation. These traces
were fitted to the Lamm equation by SEDFIT (ii)
showed the fitting residuals. The fitting residuals
were randomly distributed. The distribution of the
pentameric and decameric form of CRPMal was
analyzed by sedimentation velocity. (iii) Continuous
sedimentation coefficient distribution C(S). (iv)
Continuous molar mass distribution C(M) are shown.
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B)Hydrophobicity assay. 8-anilino-1-napthalenesulfonic
acid (ANS, 5.0 µl, 1.0 mM in TBS) was allowed to bind with
RBC-CRPMal-PC-Ca+2 complex for 5 min at 37°C. Fluorescence
spectra were scanned in a spectrophotometer with an excitation
wavelength of 365 nm. The excitation and emission band passes
were of 5 nm [35-36]. Only RBCs served as controls.
C) Oxyhemoglobin release. The RBC-CRPMal-PC-Ca+2
complex were lysed with distilled water, osmotically balanced
with TBS and exposed to superoxide radical generated from a
pyrogallol autooxidation system by adding freshly prepared
pyrogallol solution in water (10 µl, 0.02 M) for 20 min at 30°C.
The absorbance (A) of released oxyhemoglobin was measured
by Winterbourn spectrophotometric method [37] using
following equation: [oxyhemoglobin] = 119A577 - 39A630 - 89A560.
D) Turbulence fragility. To exploit the mechanical strength
of the membranes, packed RBC (0.5 ml) were suspended in TBS
(10 ml) and shaked vigorously using an orbital shaker at 2000
rpm for 4 h. A portion (0.5 ml) of suspension was withdrawn
during 0-4 h, centrifuged and the absorbance of the supernatant
was determined spectrophotometrically at 540 nm.
The hemoglobin release (%) was determined in reference to a
completely lysed cell suspension [38].
E) Scanning electron microscopy (SEM). The
morphological changes of RBCMal-CRPMal-PC-Ca+2 complexes
were evaluated by SEM (Jeol, JSM-5200). Cells were initially
fixed with 2.5% glutaraldehyde and subsequently in 1% osmium
tetraoxide in TBS, pH 7.2 for overnight. The suspensions were
dehydrated in an ethanol series (70-100%) and by the critical
point drying; subsequently gold-coated in a sputter device
and examined. Only RBCs served as controls.
Assessment of complement-regulatory proteins on RBC
after binding with CRPMal
A) Flow-cytometry. To understand the status of
complement-regulatory proteins due to binding of CRP, RBCMal-
FITC-CRP-PC-Ca+2-complex was incubated with PE-anti-CD35,
PE-anti-CD55 and PE-anti-CD59 mAbs (1:100) separately for
1h on ice. Washed cells were fixed in 1% paraformaldehyde,
acquired in Becton Dickinson FACSCalibur and analyzed by
CELLQUESTPRO software. Specific-binding was determined
by pre-incubation of 50-fold excess of unlabeled antibodies
with RBCMal-CRP-PC-Ca+2-complex. Binding of mAbs with
complement-regulatory proteins on RBCMal, in absence of CRP,
was similarly processed.
The number of complement-regulatory proteins/cell was
also determined [39] in which the median values from histograms
plot were converted to arbitrary units in a linear scale (1-1024
channels). The values for CD35, CD55, and CD59 were
normalized to the mean of the median fluorescence of the red
cell standard using following equation
Fsc = Fs (Mean Fc/Fc)
where Fsc and Fs are the corrected and uncorrected
median fluorescent channel of the sample. Fc is the median
fluorescent channel of the control stained in parallel with the
sample. Mean Fc is the mean of all the median values of the
standard control. Only RBC or isotype control served as
different negative controls.
FITC was conjugated to CRP [40]. The binding of RBC
with FITC-CRP was determined. To distinguish complementary-
regulatory proteins from the CRP-binding molecules present
on the surface of RBC, cells were pre-incubated with un-
conjugated anti-CD35, CD55 and CD59 mAbs (1:100) separately
for 1 h on ice and allowed to bind with FITC-CRPMal (10 µg/ml).
RBCN was similarly used for comparison. The binding of RBCN
with FITC-CRPTulip-PC-Ca+2-complex was also monitored.
 Only RBC or isotype controls were used.
B)ELISA. Ghost membranes from RBCMal (n=15) were
immobilized (2.0 µg/well/100 µl) on 96-well microtitre plates
(Nunc, USA) for overnight at 4°C, washed with TBS-Tween,
blocked (TBS-2% BSA), and further incubated with murine anti-
human CD35 (Clone E11), anti-human CD55 (Clone IA10), and
anti-human CD59 (Clone H19) mAbs (BD Biosciences) (1:1000)
separately. The bound complex (ghost membrane protein-anti-
complement-regulatory protein-CRPMal-PC-Ca+2) was detected
by horseradish peroxidase (HRP)-goat-anti-murine IgG (1:8000,
Cappel) using azino-bis-thiosulphonic acid (ABTS) as substrate
and quantified by an ELISA Reader (Thermo Electron
Corporation) at 405 nm.
In order to distinguish the complement-regulatory
proteins and binding sites for CRP on RBC surface, a competitive
ELISA was designed. Anti-CD35 mAbs (1:1000) and CRPMal
(10 µg/ml)-PC-Ca+2 were added onto the immobilized ghost
membrane protein. Bound complex was detected as described
above.
Additionally, bound complex was also detected by murine
anti-CRP antibodies and processed as above. The RBC-CRP
binding, in absence of complement-regulatory protein detected
with murine anti-CRP antibodies served as positive control.
The control wells were devoid of either CRP or membrane
protein. The competitive ELISA was repeated by varying
concentrations (1:4000,1:2000,1:1000,1:500,1:100) of anti-
complementary-regulatory protein mAbs with the fixed
concentration of CRPMal. The experiment was repeated using
anti-CD55 and anti-CD59 mAbs and also RBCN.
IgG is known to bind with RBC in vivo [9]. To explore the
binding site of IgG different from that for CRPMal, RBCMal were
co-incubated with human IgG (5-20 mg/ml; 100 µl) and CRPMal-
PC-Ca+2 complex (10 µg/ml; 100 µl) and then probed with
HRP-anti-human IgG. The binding of RBC with IgG was
determined in absence of CRP. Similarly, the RBCMal-CRPMal in
absence and presence of IgG (10mg/ml) was determined by
anti-CRP antibodies.
C) Western blot anlysis. Ghost membrane proteins from
RBCMal or RBCN (n=15) were electrophoresed (50 µg/ lane)
separately on SDS-PAGE gradient gel (4-12%). The separated
proteins were transferred to nitrocellulose membranes [41],
blocked (TBS-2%BSA) and incubated with CRPMal-PC-Ca+2
complex. Membranes were washed with TBS-Ca+2-Tween,
incubated with murine anti-human CRP (1:500) for overnight at
4°C and followed by HRP-rabbit anti-murine IgG (1:1000) in
TBS-BSA, washed and visualized by 3, 3-diaminobenzidine.
Similarly, CD35 antigen present on RBCMal membrane was
visualized with anti-CD35 mAb (overnight, 4°C; 1:100) followed
by HRP-goat-anti-murine IgG and processed as above.
In parallel experiment, ghost membrane protein from
malaria was co-incubated with a mixture of CRPMal-PC-Ca+2
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complex and anti-CD35 and analyzed separately using murine
anti-human CRP antibodies or HRP-goat-anti-murine IgG
and processed as above. Pre-stained markers were used as
standard to calculate Rf values. RBCN was used as control.
Similar experiments were carried out with RBCN membrane
proteins and CRPTulip-PC-Ca+2 complex.
Immunoprecipated protein was separated on SDS-PAGE,
transferred and the blots were probed with CRPMal-PC-Ca+2 and
processed as above. The experiment was repeated with RBCN
using CRPTulip-PC-Ca+2.
RBC membrane proteins (50 µg/25 µl) from malaria and
normal individuals were incubated separately with CRPMal
-PC-Ca+2 (5.0 µg) in TBS-BSA for overnight at 4°C, and
incubated with polyclonal rabbit anti-human CRP (1:100/100
µl) for overnight (4°C) followed by addition of 5 µl of protein
A–Sepharose 4B (6 mg/ml, Sigma). After incubation for
overnight at 4°C, the Sepharose bound protein complexes were
washed with cold TBS and protein samples were boiled with
4X Laemmli sample buffer for 10 mins and centrifuged.
The supernatant was further incubated with 5 µl of protein
A–Sepharose 4B for overnight, centrifuged. Supernatant was
boiled again with Laemmli sample buffer and loaded on each
lane and proteins were separated on SDS-PAGE followed by
electrophoretic transfer to nitrocellulose membrane. The blots
were probed with CRPMal-PC-Ca+2 and subsequently were
incubated with polyclonal murine anti-human CRP (1:500) and
processed as above.
The experiment was repeated with RBCN using CRPTulip-
PC-Ca+2. In parallel experiment, ghost membrane protein from
malaria was co-incubated with a mixture of CRPMal-PC-Ca+2
complex and anti-CD35 and analysed separately using
polyclonal rabbit anti-human CRP antibodies and processed
as above.
D) Scatchard analysis. To quantify the complement-
regulatory proteins on RBC due to binding with CRP, purified
murine anti-human  CD35, CD55, and CD59 mAb were iodinated
separately using Na125I [42]. The specific activity was ∼2x106
cpm/µg protein. Approximately 99% of the total radioactivity
was observed in ice-cold TCA precipitation.
RBCMal (1x109cells/tube, n = 25) in TBS-BSA were incubated
with CRPMal-PC-Ca+2 complex and subsequently incubated with
increasing doses of 125Ianti-CD35 for 1 h on ice in the presence
or absence of a 50-fold excess of unlabeled anti-CD35 mAb.
125I-anti-CD35 bound cells were washed and separated by
centrifugation. Bound reactivity in the cell pellet was measured
by a Gamma counter (Electronic Corporation of India).
The number of CD35 molecules per cell was extrapolated by
the intersection of the curve with the χ axis, and the association
constant was obtained by dividing the number of receptors
per cell by the bound/free ratio at the y axis intercepts
[43]. Measurements were done in triplicates and represented
data are means of three independent experiments. Quantification
of CD55 and CD59 on RBCs was done similarly.
In absence of CRP, RBCMal were probed with 125Ianti-CD35, anti-
CD55 and anti-CD59 separately and processed as above for
comparison. RBCN was similarly included in all the sets of
experiment.
Analysis of activation of the CRP-complement pathway
A) Quantitation of C3-deposition on RBC. Purified anti-
human C3α chain mAb, SIM 27-49 [44], was iodinated and used
for measuring C3-deposition on RBCMal (n = 25) due to triggering
of the CRP-complement pathway. RBCMal-CRPMal-PC-Ca+2 (5-20
µg/ml) complex were incubated with NHS (diluted 1:50 in TBS,
100 µl), as a source of complement, for 30 min at 37°C and
washed twice in cold TBS, and the amount of C3-deposition on
the RBCMal was quantified by incubating further with 125I-anti-
C3 mAb (3 x 105 counts/minute) for 1 h on ice. After washing,
the radioactivity in C3–anti-C3-complexes was determined by
Gamma counter. For comparison, CRP-mediated C3-deposition
on RBCN was also determined.
Anti-human CRP antibodies was used to block the binding
of CRP with RBCMal.. Reaction was also performed in absence of
CRP under identical condition. EDTA (10 mM) was used to
chelate Ca+2 required for CRP-PC-Ca+2-complex essential for
binding with RBC. In all these experiments NHS or MS (25%) or
CRP-depleted MS were used as sources of complement. De-
complemented NHS served as control.
To quantitate the C3-deposition on RBCMal-CRPMal-PC-Ca+2
(5-20 µg/ml) complex, cells were incubated with increasing doses
of 125I-anti-C3 mAb in the presence or absence of a 50-folds
excess of unlabeled anti-C3 mAb and processed similarly. The
association constant was calculated from Scatchard plot.
RBC of anemic patients showed increased surface IgG
[39], accordingly, to block the C3-deposition through these
IgG, RBCMal were pre-incubated with anti-human IgG and reaction
was continued in presence of NHS under identical condition.
C3b-containing-immune complex is known to bind with
CR1 (CD35) on RBC [45]. In order to block this binding, RBCMal
were pre-incubated with anti-CD35 mAb, subsequently allowed
these cells to bind with CRPMal-PC-Ca+2 (5-20 µg/ml) complex
and NHS. The amount of C3-deposition on these cells was
quantified as described above. Each set was repeated thrice.
B) Evaluation of CRP-complement pathway mediated
hemolysis. RBCMal(n=25)-CRPMal(10 µg/ml)-PC-Ca+2 complex
washed with ice-cold gelatin-veronal-buffered (GVB) saline
supplemented with MgCl2 (2 mM) and CaCl2 (0.15 mM) and
incubated for 30 mins at 37°C in the presence of NHS (diluted
1:50 in GVB buffer, 100 µl). The reaction was terminated with
cold GVB buffer (1.0 ml), centrifuged and the absorbance (412
nm) in the supernatant was determined.
In parallel, hemolysis was also measured in all conditions
as described for C3-deposition experiments. EGTA was used
as activator of alternative pathway. EDTA was used as the
blocker of all complement-pathways. Equal amount of RBC
suspension in distilled water was set to 100%. Experiments
were done in triplicates and reported as mean ± SD. For
comparison, CRP-complement pathway mediated hemolysis
was also carried out with RBCN.
Statistical analysis
Statistical analyses were performed using the Graph-Pad
Prism statistics software (San Diego). Results were reported as
mean ± SD and values are 2-tailed, with p <0.05 considered
statistically significant.
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Results
Higher binding of disease-associated CRPMal
with RBCMal than RBCN
Affinity-purified and well-characterized CRPMal
(Fig. 1A-C) was used in all subsequent experiments.
CRPMal that gave 3000 RU was immobilized on the CM5
chip. The association and dissociation phases of binding,
along with representative sensograms were recorded. A
concentration–dependant increase of RU value of
CRPMal-RBCMal membrane protein binding was observed
by immobilizing CRPMal (0-10 µg/ml) with a fixed
concentration of RBCMal membrane protein (50 µg/
ml)(Fig.2A). In contrast, RU for RBCN membrane protein
was lower. Significant difference between the slopes
(140.5 RU/µg/ml) of CRPMal-RBCMal membrane protein
binding as compared to CRPMal-RBCN membrane protein
(83.3 RU/µg/ml) indicated higher binding of CRPMal with
membrane protein of RBCMal than RBCN. The kinetic
curves of binding of CRPMal-RBCMal membrane protein
showed nearly 2.0-fold higher RU pick as compared
CRPMal-RBCN membrane protein (5-50 µg/ml) binding.
Fig. 2. Analysis of RBC-CRP binding: A.
Standard curve of the RBC-CRP binding by
surface plasmon resonance (SPR). Varying
concentrations of CRPMal were immobilized
onto the dextran CM5 chip. Membrane
protein (50 µg/ml) from RBCMal (-?-) or RBCN
(-?-) was used as analyte. RBC-CRP binding
was represented in arbitrary resonance
response (RU). Fig 2B-F. Alteration of
membrane parameters due to binding of RBC
with CRP. B. Turbulence fragility. The
turbulence fragility of RBCMal (-? -) was
compared with normal RBC (-? -) by
measuring the amount of released
hemoglobin (%) with time (h). Absorbance
was determined at O.D412nm. C. Osmotic
fragility. Fragility of RBCMal, before (-?-) and
after (-?-) binding of CRPMal, compared to
RBCN before (-?-) and after CRPMal binding
(-?-) was determined by incubating RBCs at
different NaCl (%) as described in materials
and methods. Data are represented in
hemolysis (%) and expressed as mean ± SD
of 4-5 independent experiments. D.
Oxyhemoglobin concentration in the
supernatant of (a) RBCN, (b) RBCMal, (c)
RBCN-CRPMal and (d) RBCMal-CRPMal complex
after exposure to superoxide radicals as
described in materials and methods. Values
are expressed as mean ± SD. E. Decreased
hydrophobicity of RBCMal membrane due to
CRP binding, RBCMal or RBCN were incubated
separately with CRPMal-PC-Ca+2 complex,
washed and subsequently ANS were allowed
to bind to the hydrophobic sites of RBC as
described in materials and methods. The
binding of ANS to RBCMal-CRPMal complex (curve 1), RBCMal (curve 2) and RBCN (curve 3) and TBS buffer (curve 4) is shown as a
measure of hydrophobicity. The graphs represent results from one of four independent experiments. F. Morphological changes
of RBC after binding with CRPMal by SEM. Pictures of micrographs of RBCN (a), RBCMal (c), RBCN-CRPMal (b) and RBCMal-CRPMal (d)
are shown. They were taken at magnification of 3500 and about 200 cells were observed.
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Binding of CRPMal altered membrane parameters
on RBCMal
In order to investigate any changes on the
membranes due to the enhanced binding of CRPMal with
RBCMal, different parameters were investigated. RBCMal
showed nearly 40-50% of hemoglobin release as
compared to 5-15% on RBCN after 4h indicating less
resistance of the membrane of patient against vigorous
turbulent flow (Fig. 2B).
At normal physiological saline concentration, RBCMal
was 3.36 ± 0.05-folds more osmotically fragile than RBCN
(Fig. 2C). However, after binding with CRPMal, additional
1.37 ± 0.14-folds increased osmofragility of RBCMal
(p<0.05) was observed, signifying CRP-mediated
additional membrane fragility of RBCMal. As expected,
enhanced hemolysis was more pronounced at lower
concentration (0.1-0.3%) of NaCl. Negligible differences
in RBCN were observed before and after binding with
CRPMal suggesting minimal binding between CRPMal with
RBCN.
RBC-CRP complex were exposed to superoxide
radicals generated by pyrogallol auto-oxidation. A ∼6-folds
more release of oxyhemoglobin was detected in RBCMal-
CRPMal compared to RBCN-CRPMal; being 45.6 ± 2 µM
vs. 7.43 ± 0.25 µM respectively (Fig. 2D, p<0.001).
Negligible release of oxyhemoglobin both by RBCMal (4.4
± 2.5 µM) and RBCN (1.12 ± 0.35 µM) was observed in
the absence of CRP.
A 4-folds increased binding of ANS (expressed as
arbitrary fluorescence intensity, a.u., Fig. 2E) with RBCMal
(8 ± 3 a.u.) along with a resultant red shift from 490nm to
515nm of the emission maximum was observed after
RBCMal-CRPMal (32 ± 5 a.u.) binding. It suggests a
significant alteration in hydrophobicity, indicating
asymmetry in the phospholipid membrane of RBCMal.
Binding of ANS with RBCN was negligible before (2 ± 1
a.u.) and after binding with CRP (3 ± 2 a.u.).
Membrane alteration induced by CRP was further
corroborated from the ultrastructural morphological
changes analyzed by SEM (Fig. 2F). RBCMal after binding
Fig. 3. The binding site for CRP on RBC is
different from complement-regulatory proteins:
A. Flow-cytometric analysis. The binding of
RBCMal with FITC-CRPMal in absence and
presence of anti-CD35 mAb was determined as
described in methods. A representative dot-plot
of binding is shown. B. ELISA. Equal amount of
membrane proteins (2 µg/well/100 µl) from RBCMal
or RBCN were coated on 96-well microtitre plates
separately, blocked and incubated with CRPMal-
PC-Ca+2 complex. In parallel set, anti-CD35 mAbs
(1:1000) and CRPMal(10 µg/ml)-PC-Ca+2 were co-
incubated with immobilized ghost membrane
protein. Bound complexes were probed with anti-
CRP antibodies as described in materials and
methods. C. SDS-PAGE, Western blotting and
immunoprecipitation profile of RBC membrane
protein after binding with CRP. Ghost membrane
protein from RBCMal was electrophoresed (50 µg/
lane) on SDS-PAGE (lane 2). The separated
proteins were transferred to nitrocellulose
membranes, blocked and incubated with
CRPMal(10.0 µg/ml)-PC-Ca+2 complex. Washed
membranes were subsequently, probed with anti-CRP antibodies and processed as described in materials and methods (lane 3).
In parallel, CRPMal-PC-Ca+2 complex and anti-CD35 mAbs was simultaneously co-incubated to RBCMal and probed as above (lane
5). Ghost membrane proteins from a representative RBCN (lanes 7) were electrophoresed and transferred to nitrocellulose membranes,
blocked and incubated with either CRPMal- (lane 7) or CRPTulip-PC-Ca+2 complex (lane 9) and processed similarly. Lane 1: Pre-stained
molecular weights marker. Lane 2-6: Membrane proteins from a representative RBCMal. Lane 2: visualized by Coomassie stain. Lane
3: Western blotting of RBCMal with CRPMal. Lane 4 Immunoprecipitation of RBCMal followed by binding with CRPMal. Lane 5: Western
blotting of RBCMal with simultaneous co-incubation of CRPMal-PC-Ca+2 and anti-CD35 mAbs. Lanes 6: Immunoprecipitation of
RBCMal with both CRPMal-PC-Ca+2 and anti-CD35 mAbs. Lane 7-10: Membrane proteins from a representative RBCN. Lane 7:
Western blotting of RBCN with CRPMal.. Lane 8: Immunoprecipitation of RBCN with CRPMal. Lane 9: Western blotting of RBCN with
CRPTulip. Lanes 10: Immunoprecipitation of RBCN with CRPTulip.
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with CRPMal induced a drastic morphological change
comprising different stages of biconcave, spherocyte,
stomatocyte, echinocyte and irregular-shaped cells (Fig.
2F d). Nearly 55 ± 6 % deformed cells were found after
binding with CRPMal as compared to only 10 ± 3% in
CRP-untreated RBCMal. Only RBCMal showed some
structural changes as compared to normal discoid-shape
indicating partial damage in diseased condition (Fig. 2F
c). RBCN, on the other hand, before (Fig 2F a) and after
(Fig 2F b) CRP-exposure retained the normal biconcave
shape. These observations established that erythrocytes
undergo considerable structural changes after interacting
CRP.
Complement-regulatory proteins were different
from binding sites for CRPMal on RBCMal
The status of complement-regulatory proteins and
binding sites for CRP on the cell surface of RBCMal was
investigated by flow cytometry. FITC-CRPMal showed
strong binding with RBCMal both in presence and absence
of anti-complement-regulatory proteins indicating that
binding sites for CRP on RBC was different than
complement-regulatory protein molecules (Fig. 3A). Only
RBC or isotype controls gives no binding suggesting the
binding was specific for CRP. The binding of FITC-
CRPTulip with RBCN was only 4 ± 1% (figure not shown).
Above observation was corroborated in a
competitive ELISA, wherein CRPMal and anti-
complement-regulatory proteins were simultaneously co-
incubated with immobilized RBCMal membrane protein.
Anti-human CRP antibodies was used to detect the bound
complexes. The binding of RBCMal with CRPMal was
comparable (O.D405nm being 0.84 ± 0.04) in presence and
absence of anti-CD35 antibodies (Fig. 3B) suggesting no
apparent competition between CD35 molecule and binding
site for CRP on RBCMal. Probing with anti-CRP antibodies,
Fig. 4. Differential expression of complement-
regulatory proteins on RBC by Scatchard
analysis: A. Binding of 125I-anti-CD35 to
RBCMal. RBCMal (1x109/tube) in TBS-BSA were
incubated for 1 h on ice with increasing doses
of 125I-anti-CD35. The bound and unbound
anti-CD35 was separated at 4°C and the bound
radioactivity was determined as described in
materials and methods and plotted against
added 125Ianti-CD35. To evaluate the specific
nature of binding, a 50-folds excess of
unlabeled antibodies was added. Specific-
binding (-?-) was determined by calculating
the difference between total binding (-?-) and
nonspecific binding (-? -). Results are
expressed as mean ± SD of data from triplicate
experiments. Inset: Association constant (Ka)
and the number of CD35 molecules per RBCMal
were determined by Scatchard plots of the
binding data. A representative Scatchard plot
showing bound/free against the various
amounts of bound 125I-anti-CD35 is shown. B. Reduced complement-regulatory proteins on RBCMal in presence of CRPMal. After
binding of CRPMal with RBCMal, the number of CD35 molecules/RBCMal were determined using 
125I-anti-CD35 as described in
materials and methods. Specific-binding (-?-) was obtained by the difference between total binding (-?-) and binding in
presence of unlabeled anti-CD35 (-?-). Inset: Association constant of the binding of 125I-anti-CD35 with RBCMal-CRPMal complex
was determined from the Scatchard plot. C. Complement-regulatory proteins on RBCN . Scatchard analysis was repeated similarly
using RBCN. Specific-binding (-?-) was calculated by the difference between total binding (-?-) and binding in presence of
unlabeled CD35 (-?-). Results are expressed as mean ± SD of data from triplicate experiments. Inset: Representative Scatchard
plot of the binding of 125ICD35 to RBCN in which bound/free was plotted against the various amounts of bound anti-CD35. D-F.
Differential expressions of CD35 (D), CD55 (E) and CD59 (F) molecules on RBC from 10 individual patients, before or after
exposure to CRPMal, were shown. Similar studies with RBCN (N=10) are presented before or after exposure to CRP. p<0.001 for the
number of CD55 molecules on RBCMal before and after exposure to CRP, paired t test. p<0.004 for the number of CD35 molecules
on RBCMal before and after exposure to CRP, paired t test. p<0.07 for the number of CD59 molecules on RBCMal before and after
exposure to CRP, paired t test.
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no significant variations in the absorbance were observed
with increasing concentration of anti-CD35 antibodies
(1:4000 to 1:100), implying no competition for the binding
of anti-CD35 and CRP on RBCMal. Similar result was
observed in presence of anti-CD55 and anti-CD59
antibodies.
The molecular identity of the specific protein on the
RBC membrane that reacts with CRPMal, revealed four
distinct bands corresponding to 112, 82,149 and 57 kDa
on RBCMal by Western blotting analysis (Fig. 3C, lane 3).
In parallel, when the RBCMal membrane blot was co-
incubated with both CRPMal and anti-human CD35
antibodies similar four band profiles were observed (lane
5).
To check whether CRPMal can bind with the native
structure of RBC membrane protein, an
immunoprecipitation experiment was designed. The
specific molecules present on the membrane that reacts
with CRPMal were immunoprecipitated and analyzed by
Western blotting. Immunocomplex of RBCMal membrane
proteins with CRPMal showed same four bands (lane 4).
Co-immunoprecipitated RBCMal membrane proteins after
co-incubating with both CRPMal and anti-CD35 antibodies
also showed similar four proteins (lane 6).
In contrast, only a 149kDa protein was observed on
membrane of RBCN reacting with CRPMal (lane 7). Similar
band on RBCN membrane proteins was immuno-
precipitated, which reacted with CRPMal (lane 8). This
common band was found also on RBCMal. Thus, this may
not be a disease-associated molecule. No band was
detected after reacting RBCN membrane with CRPTulip
before (lane 9) and after (lane 10) immunoprecipitation.
Decrease in complement-regulatory proteins on
RBCMal after binding with CRPMal
The number of complement-regulatory proteins was
always less on RBCMal compared to RBCN (p<0.05) (Fig.
4-5). Next, we have explored the possible role of CRP-
induced perturbed membrane structure of RBCMal, to
assess the status of CD35, CD55 and CD59 molecules
using anti-CD35/CD55/CD59 antibodies as respective
probes by Scatchard analysis (Fig. 4), flow-cytometry,
Western blot (Fig. 5B-C) and ELISA (Fig. 5A),
Accordingly, after specific-binding of RBCMal with CRPMal,
the status of complement-regulatory proteins on RBCMal
was monitored.
After binding with CRPMal, the presence of less
number of CD35/RBCMal was reduced from 630 ±124 to
255 ± 58 as revealed by Scatchard analysis (Fig. 4A-B,
p<0.001). Similarly, decreased number of CD55/RBCMal
was observed after binding with CRPMal; reduction being
from 700 ± 185 to 363 ± 194. The association constant
(Ka) of the binding of 
125Ianti-CD35 or 125Ianti-CD55 or
125Ianti-CD59 with respective CD35 or CD55 or CD59
Fig. 5. Down regulation of complement-regulatory
proteins on RBCMal after binding with CRPMal: A. ELISA.
RBCMal and/or RBCN (2 µg/well/100 µl) were coated on 96-
well microtitre plate. The number of CD35, CD55 and CD59
were quantified in absence and presence of CRPMal-PC-
Ca+2 using anti-complementary regulatory protein
antibodies and detected using HRP-anti-murine IgG as
described in methods. Data are expressed as mean ± SD.
B-C. Western blot analysis. B. RBCMal were electrophoresed
on SDS-PAGE and visualized by Coomassie stain (lane 2).
The protein was transblotted onto nitrocellulose. The blot
was probed with purified anti-CD35 mAb (lane 3) In parallel,
transblotted RBCMal was co-incubated with CRPMal(10.0 µg/
ml)-PC-Ca+2 complex followed by addition of anti-CD35
mAbs (lane 4). Bound complex in both the blots were
detected with HRP-goat-anti-murine IgG antibodies as
described in materials and methods. Lane1: Molecular
weight markers. C. RBCN from three individuals (N1, N2 and
N3) probed with either purified anti-CD35 mAb or anti-
CD55 mAb. In parallel, transblotted RBCMal from three
patients (P1, P2 and P3) with anti-CD35 mAbs or anti-CD55 mAb separately were shown. In parallel, transblotted RBCMal (P1, P2 and
P3) was co-incubated with CRPMal(10.0 µg/ml)-PC-Ca
+2 complex and anti-CD35 mAbs or anti-CD55 mAb separately. Bound complex
in both the blots were detected with HRP-goat-anti-murine IgG antibodies as described in materials and methods.
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molecules on RBC were shown in absence and presence
of CRP (Table 1). In presence of CRP, the Ka of these
three molecules for their respective antibodies was
reduced probably due to altered membrane parameters
of RBCMal.
However, the number of CD59/RBCMal did not
change appreciably even after binding with CRPMal as
corroborated by earlier reports [39]. Similar patterns were
observed in all the patients included in this study (p<0.01),
as shown for 10 individual patients, before and after CRP
binding, along with 10 normal volunteers (Fig. 4D-F).
The number of complement-regulatory molecules/cell on
RBCN in presence and absence of CRP was more or
less constant (Fig. 4C).
The observation was further corroborated by FACS
analysis. A decrease in the CD35+RBCMal from 60 ± 4%
to 20 ± 5% was observed after sensitizing with CRPMal.
Similar decrease in the CD55+RBCMal cells from
78 ± 3% to 17 ± 4% was always observed on RBCMal. In
contrast, decrease in CD59+ cells was low from 86 ± 3%
to 60 ± 5%.
The decrease of number of CD35 molecules/cell
before and after CRP-treatment was 599 ± 124 to
215 ± 101 whereas the decrease of CD55 molecule/cell
was from 685 ± 154 to 363 ± 126. However, no significant
change in CD59 molecules/cell was observed; values
being 16,218 ± 2214 and 14,881 ± 1762 respectively.
In contrast, insignificant loss of complement-regulatory
proteins was observed on RBCN in presence of CRPMal.
Similar trend was further corroborated by an
inhibition-ELISA (Fig. 5A) wherein anti-CD35 and
CRPMal were added simultaneously on immobilized
RBCMal membrane proteins. Bound complexes were
detected using secondary antibody specific for the
measurement of complement-regulatory proteins.
Binding of anti-CD35 with RBCMal was significantly
reduced in presence of CRP as reflected in the decreased
O.D405nm of 0.139 ± 0.035 from 0.449 ± 0.057 in absence
of CRP demonstrating lowering of these molecules due
to RBCMal-CRP binding (Fig. 5A). Decrease in CD55
molecules were also observed in presence of CRP. Small
differences in absorbance both in presence and absence
of CRP signify less reduction of CD59 molecules. In
contrast, no major changes in the absorbance were
observed before and after binding of CRPMal with RBCN
(Fig. 5A).
In order to pinpoint the effect of CRP, the ELISA
was repeated with varying concentration of anti-CD35
antibody (1:100 to 1:4000) with a fixed concentration of
CRP. A decrease in the absorbance was observed with
increase in dilution and reached a plateau after 1:1000.
Similar result was obtained using anti-CD55 antibody. In
contrast, no major changes in absorbance were observed
with anti-CD59 antibody. In a competitive ELISA, where
anti-CD35, CD55 and CD59 antibody concentration were
titrated, keeping the concentration of CRP constant, the
binding of RBC decreases with decreasing concentration
of anti-complement-regulatory proteins. Therefore, it may
be envisaged that there was no apparent steric hindrance
created by bound CRP. However, the possibility of steric
hindrance could not be ruled out.
Western blot analysis using anti-CD35 antibodies,
as an analytical probe, showed a single band (205 kDa)
on RBCMal in presence and absence of CRP, consistent
with the reported molecular weight of CD35 on RBCN
(Fig. 5B). Therefore, CRPMal is possibly not competing
to bind with CD35 molecules on RBC. Similar result was
observed with anti-CD55 and anti-CD59 antibodies.
Similar patterns were observed in all the patients
included in this study. A representative profile of three
patients, before and after CRP binding, along with three
normal volunteers has been shown (Fig. 5C). Normal
individuals showed no major differences before and after
CRP-treatment. The complement-regulatory molecules/
cell on RBCN in presence and absence of CRP was
stronger than on RBCMal.
Table 1. Association constants of complement-regulatory proteins /RBCMal after binding with CRP. RBC was
incubated with radioactive anti-complement-regulatory proteins mAbs. A 50-folds excess of unlabeled mAbs
was used to evaluate specific nature of binding. Bound radioactivity was measured. The apparent Ka values
and numbers of complement-regulatory proteins per cell were calculated from Scatchard analysis.
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CRP triggered complement-cascade with
concomitant C3-deposition
The potential of CRPMal to activate the complement
pathway was investigated in the presence of NHS, by
quantifying C3-deposition using 125Ianti-C3 mAbs. A
gradual increase in C3-deposition on RBCMal was
observed with increasing concentrations of CRPMal (Fig.
6A). At physiological concentration (10 µg/ml), CRP is
capable of inducing maximum C3-deposition (90 ± 6%)
on RBCMal. A 50-folds excess unlabelled anti-C3 mAbs
competed with the binding of 125Ianti-C3 mAbs (Fig. 6B).
The apparent association constant (Ka) for C3-deposition
triggered by CRP was 1.13 ± 0.89x107 M-1 and the number
of C3-molecules bound per cell was 2.5 ± 0.45x106 as
determined by Scatchard analysis. On the other hand,
significant low C3-deposition was observed on RBCN
(10±2%), possibly due to low binding of CRPMal and as a
result less activation of complement.
To further demonstrate the role of CRPMal, RBCMal-
CRPMal binding was initially blocked by using either anti-
CRP antibodies or EDTA separately and subsequently
their effect on C3-deposition was investigated.
Preincubation of CRPMal with anti-CRP antibodies showed
reduced C3-deposition from 90 ± 6% to 49 ± 8%.
Similarly, EDTA was used to inhibit the Ca2+ dependent
binding of CRPMal with RBCMal resulting only 50 ± 6%
C3-deposition. In absence of CRPMal, C3-deposition
through pathways other than CRP was only 52 ± 4%,
suggesting ∼42-45% of C3-deposition possibly through
CRPMal-complement pathway.
CRP is able to activate the classical complement
pathway serving as a potential link between complement
activation and innate immune system [20]. However, CRP
is unable to trigger the alternate pathway [46]. As EGTA
is known to trigger alternate pathway, C3-deposition
through this pathways was measured, being only 23 ±
3%. However, even in presence of EGTA, CRP could
not trigger C3-deposition (S1). However, even in presence
of EGTA, CRP could not trigger alternate pathway
mediated C3-deposition, being 2 ± 1%.
Fig. 6. Activation of the CRP-
complement pathway: A. Estimation of
C3-deposition. RBC-CRPMal-PC-Ca+2
complex (-?-) was incubated at 37°C for
30 min with NHS as source of
complement. Activation of CRP-mediated
complement pathway was monitored by
C3-deposition on RBC using 125I-anti-C3
mAb as described in materials and
methods. C3-deposition is represented
as percentage of specific-binding of anti-
C3 mAb (mean ± SD of triplicate values).
Additionally, RBCMal of same patient was
initially incubated with purified anti-
CD35 followed by binding with CRPMal-
PC-Ca+2 complex (-?-) and C3-deposition
was compared in presence of NHS.
Deposition of the C3 on RBCN (-? -)
without pre-incubation with CD35 is
shown. B. Scatchard analysis of
deposited C3-molecules on RBC: RBCMal
(1x109)-CRPMal(10.0 µg/ml)-PC-Ca+2
complex was incubated with NHS at 37°C
for 30 min. Activation of CRP-
complement pathway was monitored by
C3-deposition on RBC surface using increasing amounts of 125I-anti-C3 mAb as described in materials and methods (mean ± SD
of data from triplicate experiments). Specific-binding (-?-) was calculated by the difference between total binding (-?-) and
binding in presence of unlabeled anti-C3 mAb (-?-). Inset: Scatchard plot of the binding of 125I-anti-C3 mAb to RBCMal. C. CRP-
complement-mediated hemolysis. Correlation (r2=0.94) between CRP-complement pathway-mediated hemolysis (%) and binding
(%) of RBC from 10 individual patients with CRPMal (-?-) are shown. Similar parameters were shown with RBCN (-?-). Results are
expressed as mean of ± SD of data from different experiments. D. Correlation (r2=0.92) between hemoglobin concentration (g/dl)
and number of CD35 molecules on RBCMal from 10 individual patients (-?-, n=10). Similar parameters with RBCN (-?-) are shown
for comparison.
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When serum from normal (NHS) and malaria
patients (MS) were used as sources of complements
separately, comparable C3-deposition in presence of
CRPMal was observed on RBCMal being 92±2% and
90±6% respectively. This suggested undisturbed
complement components in diseased state, as observed
by our previous reports in other diseases [46-47]. Similar
result was observed in presence of CRP-depleted
patient’s sera (91±5%). In contrast, as expected, heat
inactivated NHS unable to deposit C3-molecules on
RBCMal both in presence (4±2%) and absence of CRPMal
(2±1%). Only buffer showed negligible reading.
Additionally, to explore the role of CD35 in CRP-
mediated C3-deposition, RBCMal was initially incubated
with anti-CD35 and subsequently with CRPMal (Fig. 6A).
C3-deposition was reduced from 90 ± 6% to 70 ± 5%.
Both NHS and MS, used as source of complements
separately, showed comparable reading. Anti-CD35
antibodies possibly acted as a surrogate for C3-deposition
by binding with C3-bound Immune complexes (ICs).
Approximately 20-22% of the C3-deposition may be
considered to be through CR1-mediated
erythrophagocytosis and anti-CD35 antibodies.
CRP-mediated complement-pathway triggered
enhanced hemolysis of RBCMal
Though the interplay of a several pathways has been
reported for hemolysis of RBCs (S2), our aim was to
dissect the CRP-mediated complement-cascade.
Accordingly, the fate of RBCMal, after CRP-mediated
C3-deposition, was investigated, using NHS as
complement source (Fig. 6C). A significantly higher CRP-
mediated hemolysis of RBCMal was observed compared
to RBCN; being 85 ± 6% vs.13 ± 8% (p<0.001). Higher
binding of RBCMal with CRP, even at normal physiological
concentration, is possibly responsible for such enhanced
hemolysis. A good correlation was observed between the
binding of CRPMal with RBCMal and their respective
hemolysis (r2=0.94).
Comparable hemolysis was observed using patients’
serum (87 ± 4%), CRP-depleted serum (82 ± 7%) and
NHS as sources of complement, signifying the in vivo
scenario. As CRP-mediated complement-activation
requires Ca+2, addition of EDTA to chelate Ca+2 causes
drastic reduction of hemolysis (24 ± 7%). Reduced
hemolysis (30 ± 8%) was also observed in presence of
anti-CRP antibodies establishing the direct role of CRP.
De-complemented serum, as expected, showed complete
abolition of hemolysis (3 ± 1%). In contrast, in absence
of CRP, when all other pathways are unblocked, only 26
± 4% hemolysis of RBCMal was observed under identical
condition.
Additionally, alternative pathway-mediated hemolysis
was 20 ± 3% as triggered by EGTA. However, in presence
of EGTA, CRP could not triggered alternate pathway-
mediated hemolysis (2 ± 1%). Negligible hemolysis (4 ±
2%) was observed when EDTA was used suggesting
blocking all complement pathways. Taken together, we
have conclusively demonstrated a new mechanism of
CRP-mediated complement pathway, for the clearance
of damaged erythrocytes in malaria (S1).
Role of CRP in IgG-mediated reduction of
complement-regulatory proteins
Human CRP bears functional similarity with human
IgG [29, 45]. IgG after its deposition on RBCMal is reported
to reduce the levels of complement-regulatory proteins
[39]. Therefore, we wanted to explore the role of CRP in
IgG-mediated reduction of complement-regulatory
proteins. Accordingly, we have checked the binding of
CRPMal with RBCMal using anti-CRP antibodies as
detecting probe. Comparable absorbance in presence
(0.91 ± 0.05) and absence (0.87 ± 0.04) of physiological
concentration of IgG (10 mg/ml) was observed. The
binding IgG with RBCMal in presence (0.83 ± 0.03) and
absence (0.77 ± 0.06) of CRP was comparable as
detected by anti-human IgG. As RBCMal-CRPMal binding
could not be inhibited by IgG, it may be envisaged that
binding pocket for IgG is different from that for CRP on
RBCMal.
IgG is known to mediate C3-deposition on RBC [45].
C3-deposition was 90 ± 6% in presence both CRP and
IgG. To block IgG mediated C3-deposition, RBCMal was
pre-incubated with anti-human IgG and subsequently
incubated with CRPMal. C3-deposition was decreased
from 90 ± 6% to 80 ± 8% indicating only 8-11% C3-
deposition through human IgG. However, in absence of
both CRP and IgG, hemolysis was 25 ± 4%. Thus
contribution of CRP, IgG, CD35 and alternate pathway in
C3-depositions was 42-45%, 8-11%, 20-22% and 20-23%
respectively; 7-10% may be accounted for other
unidentified pathways.
Discussion
The pathogenesis of malarial anemia is multi-factorial.
The patients, included in this study, had low hemoglobin
concentration (4.5-7.8 g/dl). Our aim was to address for
clues of immunologic mechanisms and to identify some
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key-players accounting for premature clearance of RBC
contributing towards hemolysis resulting anemia. Surface-
membrane alterations on RBCMal suggested occurrence
of damaged cell surface (Fig. 2B-F). This may be
responsible for higher binding of damaged RBCMal with
CRPMal (Fig. 2A), which causes further alterations of
these membranes (Fig. 2B-F). Additionally, we have
dissected a number of pathways regulating RBC
destruction which possibly contributing towards anemia
due to higher binding of damaged RBCMal with CRP (S2).
To protect against complement-mediated cell lysis,
RBCN, in general, expresses more complement-regulatory
proteins on their surface [39]. The expressions of CD35
molecules on RBCMal were significantly low as compared
to RBCN (p<0.001). The reduction was further enhanced
due to specific-binding of CRPMal with RBCMal. A good
correlation (r2=0.92) between hemoglobin concentration
and CD35 molecules/cell on RBCMal (Fig. 6D) suggested
that the RBCMal are more prone to hemolysis and probably
may crave the pathway to anemia in the milieu of malaria
infection. Thus, it conclusively supports the idea that
CRPMal possibly is an important contributor to the
accelerated destruction of RBCs and may thus help to
remove damaged RBC in malaria.
The presence of damaged RBCs in malaria
compared to normal (Fig. 2B-F) may be due to reactive
oxygen species (ROS) [49] or stress or disease-induced
stimulators or key functioning of some enzymes in inflamed
condition [50] with externalization of phosphatidylserine
(PS). It may also be exposed following RBC interaction
with leucotriens of activated neutrophils. This damage
leads to molecular modifications of its outer cell membrane
causing a flip-flop between the membrane bilayer,
resulting in enrichment of the outer leaflet in
phosphatidylserine and phosphatidylethanolamine and/or
band 3. Thus the membrane phospholipids become
susceptible to hydrolysis by secretory phospholipase,
generating lysophospholipids and  lysolecithin.
At sites of inflammation and tissue necrosis, CRP
binds to cell membranes of damaged and necrotic cells,
but not with normal cells. In biological membranes, PC is
present in the outer layer as the polar head group of lecithin
and sphingomyelin.  Due to the presence of lysolecithin
within the outer layer, more CRP can bind to the PC of
lecithin [51-52].  Such binding required the addition of
submicellar concentrations of lysolecithin, establishing
requirement for cell damage for binding of the protein to
cell membranes at inflammatory sites. PC might however,
be altered, and exists in a different pattern in cell
membrane.
The previous study from our laboratory conclusively
demonstrated glycosylated molecular variants of human
CRP in different pathological conditions including malaria
[16, 27]. CRP is not only produced from hepatic cells but
also from local inflammatory cells [16, 53]. It is suggested
that upregulation/downregulation of some enzymes or
cytokines or their modulators or other extra-cellular
signaling molecules in local inflammatory cells possibly
responsible for induction of altered CRP during malaria
infection (S1). The possibility of induction of some post-
translational enzyme regulation cannot be ruled out as
preferential expression of certain genes in the presence
of toxic materials, released by parasites, may facilitate
the changes in CRPMal during post-translational
modification. The small changes observed in CRPMal (Fig.
1) are possibly crucial for specific biological functions in
vivo. The minute changes observed in CRPMal as
compared to CRPTulip make these two molecules different
but their native pentraxin structures remained almost the
same (Fig. 1).
Circulating IgG could modify RBC membrane [39].
As CRP reported to share many functional properties
with IgG, therefore, it was worthwhile to identify the
probable role of CRPMal in modulating the surface
membrane of RBCMal. Significant alterations of their
membranes were conclusively demonstrated (Fig. 2)
wherein a few specific molecules (112, 82,149 and 57
kDa) on RBCMal were seen after binding with CRPMal
(Fig. 3). A common protein (149 kDa) both on RBCMal
and RBCN may not be a disease-associated molecule.
These CRP-binding molecules are distinct from
complement-regulatory proteins on RBC (Fig. 3).
Surface deposition of parasite antigen on RBCMal
[49] and the binding of CRP with parasite antigens [54]
suggested that a few of these proteins might be parasite-
derived protein (Fig. 3C). The RBCMal, used in our
experiment, comprises both infected and uninfected
population, which is to some extent damaged due to altered
membrane parameters in RBCMal as compared to normal
(Fig. 2). Due to damage imposed on this RBCMal, probably
the conformation or mosaics of distribution of CRP-binding
molecules are altered. Further investigation on the nature
of these CRP-binding molecules is underway.
Our observation supports the idea that the surface
abnormalities affect both infected and uninfected RBCs
because the fluorescence histograms were unimodal and
not bimodal. We were unable to detect two separate
populations of cells with drastically different fluorescence
from each other. Furthermore, surface changes observed
in SEM are unlikely to come from the sole contribution of
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only 7-8% infected red cells. The small percentage of
infected cells could not contribute towards such lowering
of complement-regulatory proteins after CRP binding. As
RBCMal are both stressed and damaged, they are possibly
quite different from RBCN. Therefore, it is quite possible
that the major causes of anemia are the destruction of
large number of uninfected along with infected RBCs,
which enhanced in the presence of CRPMal.
CRP behaving as a lectin [55] may affect the
membrane features such as fluidity. When RBCMal were
exposed to superoxide radicals, they released ∼10-folds
more of oxyhemoglobin (Fig. 2D) in presence of CRPMal
as compared to its absence suggesting enhanced
susceptibility of RBCMal by superoxide damage. Still other
mechanism of the changes in membrane components
might be connected with the production of oxygen free
radical species [56].
RBCN are protected from autologous complement-
mediated lysis by membrane-anchored complement-
regulatory proteins. Deficiencies of these proteins on RBC
are common in hemolytic anemia [57], paroxysmal
nocturnal hemoglobinuria [58], systemic lupus
erythematosus and other autoimmune diseases [59]. We
also found similar deficiencies in malaria patients, at
diagnosis, which were more pronounced in presence of
CRPMal (Fig. 4-5). However, in contrary to 2-4-folds
reduction of both the CD35 and CD55 in presence of
CRP, the changes of CD59 were marginal (Fig. 4-5) as
corroborated by earlier reports [39]. The mosaics of
distribution of these molecules on cell surface are altered
with a possible slight change in their conformation resulting
in decrease in affinity. So, evidently in presence of
CRP, the Ka of these molecules is lowered. Also the
possibility of steric hindrance created by CRP molecule
could not be ruled out. However, many theories are
underway to propose for the reduction of complement-
regulatory proteins. These molecules are decreased
possibly due to partial or complete cleavage by proteases
and/or phospholipases released by schizonts [39].
Whatever may be the mechanisms responsible for these
changes, reduction of these molecules are quite common
in Pf infection which clearly demonstrated CRP-mediated
enhanced reduction of complement-regulatory proteins
elucidating an underway mechanism for the pathology of
anemia. However, role of bone-marrow dysfunction,
genetic disorder and other factors may not be ruled out.
CR1 has recently implicated in rosette formation [6].
CRP, by lowering its number, may prevent the adhesion
of RBCMal, which is possibly initiated by the parasites.
As CR1 is known to bind with C3b to opsonize RBC,
thus the contribution of CR1 was analyzed in
CRP-triggered C3-deposition and subsequent hemolysis
(S1). Destruction of RBC may occur via different
mechanisms involving the interaction with parasite
antigens, anti-parasite antibodies, immune complexes
(ICs) and complement degradation products present in
circulation, by erythrophagocytosis, complement-attack,
or the removal of RBC-bound antibodies or ICs [S2, 60-
65].
Initial study hinting CRP-mediated hemolysis [27],
led us to relate its induced level and postulate a mechanism
of CRP-mediated fate of RBCs. In conclusion, binding
of CRPMal through a few specific molecules on RBCMal
lowered the number of complement-regulatory proteins
and thus accelerates the removal of the damaged RBCs
from circulation by initiating complement-cascade. To the
best of our knowledge, this is the first report to correlate
CRP and complement-regulatory proteins with the
pathology of Pf anemia.
Abbreviations
BSA (Bovine serum albumin); CRP (C-reactive
protein); CRPMal (Purified CRP from patients with
malaria); ELISA (Enzyme-linked immunosorbent assay);
EDTA (Ethylene diamine tetra acetic acid); EGTA
(Ethylene Glycol tetra acetic acid); FACS (Fluorescence
activated cell sorter); FITC (Fluorescein isothiocyanate);
HRP (Horseradish peroxidase); IgG (Immunoglobulin G);
MS (Serum from malaria patients); mAb (Monoclonal
antibody); Mal (Malaria); NHS (Normal human serum);
Pf (Plasmodium falciparum); PC (Phosphocholine);
PAGE (Polyacrylamide gel electrophoresis);
PE (Phycoerythrin); RBC (Red blood cells); RBCMal (Red
blood cells from malaria); RBCN (Red blood cells from
normal individuals); RBC-CRP complex (RBC were
complexed with CRPMal); SDS (Sodium dodecyl
sulphate); SEM (Scanning Electron Microscopy);
SPR (Surface Plasmon Resonance); TCA
(Trichloroacetic acid).
Acknowledgements
WA is a SRF of Council of Scientific and Industrial
Research (CSIR). We gratefully acknowledge IICB
(CSIR), Department of Science and Technology and the
Indian Council of Medical Research, Govt. of India for
their financial support. We extend our sincere thanks to
Ansar/Habib/Roy/Mandal/MandalCell Physiol Biochem 2009;23:175-190
189
References
1 Owuor BO, Odhiambo CO, Otieno WO,
Adhiambo C, Makawiti DW, Stoute JA:
Reduced immune complex binding
capacity and increased complement
susceptibility of red cells from children
with severe malaria-associated anemia.
Mol Med 2008;14:89-97.
2 Menendez C, Fleming AF, Alonso PL:
Malaria-related anemia. Parasitol Today
2000;16:469-476.
3 Stoute JA, Odindo AO, Owuor BA, Mibei
EK, Opollo MO, Waitumbi JN: Loss of
red blood cell-complement regulatory
proteins and increased levels of
circulating immune complexes are
associated with severe malarial anemia. J
Infect Dis 2003;187:522-525.
4 Miwa T, Song WC: Membrane
complement regulatory proteins: insight
from animal studies and relevance to
human diseases. Int Immunopharmacol
2001;1:445–459.
5 Parker CJ: Regulation of complement by
membrane proteins: an overview, Curr
Top Microbiol Immunol 1992;178:1–6.
6 Rowe JA, Moulds JM, Newbold CI, Miller
LH: P. falciparum rosetting mediated by
parasite-variant erythrocyte membrane
protein and complement-receptor 1.
Nature 1997;388:292-295.
7 Woodruff AW, Ansdell VE, Pettitt LE:
Cause of anemia in malaria Lancet
1979;1:1055–1057.
8 Price RN, Simpson JAF, Nosten F,
Luxemburger C, Hkirjaroen L, ter Kuile
F, Chongsuphajaisiddhi T, White NJ:
Factors contributing to anemia after
uncomplicated malaria. Am J Trop Med
Hyg 2001;65:614– 622.
9 Reinagel ML, Gezen M, Ferguson PJ,
Martin EN, Taylor RP: The primate
erythrocyte complement receptor (CR1)
as a privileged site: binding of
immunoglobulin G to erythrocyte CR1
does not target erythrocytes for
phagocytosis. Blood 1997;89:1068–
1077.
10 Schreiber AD, Frank MM: Role of
antibody and complement in the immune
clearance and destruction of
erythrocytes. I. In vivo effects of IgG
and IgM complement-fixing sites. J Clin
Invest 1972;51:575-582.
11 Madi N, Paccaud JP, Steiger G, Schifferli
JA: Immune complex binding efficiency
of erythrocyte complement receptor 1
(CR1). Clin Exp Immunol 1991;84:9–
15.
12 Reinagel ML, Taylor RP: Transfer of
immune complexes from erythrocyte
CR1 to mouse macrophages. J Immunol
2000;164:1977–1985.
13 Black S, Kushner I, Samols D: C-reactive
protein. J Biol Chem 2004;279:48487-
48490.
14 MacLeod CM, Avery OT: The occurrence
during acute infection of a protein not
normally present in the blood. II.
Isolation and properties of the reactive
protein. J Exp Med 1941;73:183-190.
15 Pepys MB, Baltz ML: Acute phase
proteins with special reference to C-
reactive protein and related proteins
(pentaxins) and serum amyloid A protein.
Adv Immunol 1983;34:141-212.
16 Das T, Sen A, Kempf T, Pramanik SR,
Mandal C, Mandal C: Induction of
glycosylation in human C-reactive
protein under different pathological
conditions. Biochem J 2003;373:345-
355.
17 Das T, Mandal C, Mandal C: Variations
in binding characteristics of glycosylated
human C-reactive proteins in different
pathological conditions. Glycoconj J
2004;20:537-543.
18 Das T, Mandal C, Mandal C: Protein A-a
new ligand for human C-reactive protein.
FEBS Lett 2004;576:107-113.
19 Marnell L, Mold C, Du Clos TW: C-
reactive protein: ligands, receptors and
role in inflammation. Clin Immunol
2005;117:104–111.
20 Kaplan MH, Volanakis JE: Interaction
of C-reactive protein complexes with the
complement system. I. Consumption of
human complement associated with the
reaction of C-reactive protein with
pneumococcal C-polysaccharide and with
the choline phosphatides, lecithin and
sphingomyelin. J Immunol
1974;112:2135-2147.
21 McGrath FD, Brouwer MC, Arlaud GJ,
Daha MR, Hack CE, Roos A: Evidence
that complement protein C1q interacts
with C-reactive protein through its
globular head region. J Immunol
2006;176:2950-2957.
22 Volanakis JE, Clements WL,
Schrohenlohr RE: C-reactive protein:
purification by affinity chromatography
and physiochemical characterization. J
Immunol Methods 1978;23:285–295.
23 Christner RB, Mortensen RF: Specificity
of the binding interaction between human
serum amyloid P-component and
immobilized human C-reactive protein.
J Biol Chem 1994;269:9760-9766.
24 Lowry OH, Rosebrough NJ, Farr AL,
Randall RJ: Protein measurement with
folin phenol reagent. J Biol Chem
1951;193:265-275.
25 Laemmli UK: Cleavage of structural
proteins during the assembly of the head
of bacteriophage T4. Nature
1970;227:680-685.
26 O’ Farrell PZ, Goodman HM, O’ Farrell
PZ: High resolution two-dimensional
electrophoresis of basic as well as acidic
proteins. Cell 1977;12:1133-1141.
27 Ansar W, Bandyopadhyay SM,
Chowdhury S, Habib SH, Mandal C: Role
of C-reactive protein in complement-
mediated hemolysis in Malaria. Glycoconj
J 2006;23:233-240.
28 David M, Pepys MB, Hawkins PN:
Metabolic and Scintigraphic studies of
radioiodinated human C-reactive protein
in health and diseases. J Clin Invest
1993;91:1351-1357.
Alfredo Toreno (Servicio de Immunologia, Centro
Nacional de Microbiologia, Instituto de salud Carlos III
Majadahonda, Madrid, Spain) for his generous gift of anti-
C3 monoclonal antibody; Radhaballav Bhar and Pallab
Dasgupta from School of Laser Science and Engineering,
Jadavpur University, Jadavpur, Kolkata for their help in
preparation of slides for SEM; Suchandra Chowdhury
and Kausik Bhattacharya for FACS analysis and Asish
Mallick for his excellent technical assistance.
C-reactive Protein and Complement-Regulatory Proteins Cell Physiol Biochem 2009;23:175-190
190
2 9 Thompson D, Pepys MB, Wood SP: The
physiological structure of human C-
reactive protein and its complex with
phosphocholine. Structure 1999;7:169–
177.
30 Schuck P: Size-distribution analysis of
macromolecules by sedimentation
velocity ultracentrifugation and lamm
equation modeling. Biophys J
2000;78:1606-1619.
31 Lebowitz J, Lewis MS, Schuck P: Modern
analytical ultracentrifugation in protein
science: A tutorial review. Protein Sci
2002;11:2067-2079.
3 2 Schuck P: On the analysis of protein self-
association by sedimentation velocity
analytical ultracentrifugation. Anal
Biochem 2003;320:104-124.
33 Gotschlich EC, Edelman GM: C-reactive
protein: a molecule composed of subunits.
Proc Natl Acad Sci USA 1965;54:558-
566.
34 Sharma V, Chatterjee M, Mandal C, Sen
S, Basu D: Rapid diagnosis of Indian
visceral leishmaniasis using achatinin H,
a 9-O-acetylated sialic acid binding
lectin. Am J Trop Med Hyg 1998;58:551-
554.
35 Mukherjee K, Chowdhury S, Mondal S,
Mandal C, Chandra S, Bhadra RK, Mandal
C: 9-O-acetylated GD3 triggers
programmed cell death in mature
erythrocytes. Biochem Biophys Res
Commun 2007;362:651-657.
3 6 Ghosh S, Bandyopadhyay S,
Bhattacharya DK, Mandal C: Altered
erythrocyte membrane characteristics
during anemia in childhood acute
lymphoblastic leukemia. Ann Hematol
2005;84:76-84.
3 7 Winterbourn CC: Oxidative reactions of
hemoglobin. Methods Enzymol
1990;186:265-272.
3 8 Hamidi M, Tajerzadeh H, Dehpour AR,
Rouini MR, Ejtemaee-Mehr S: In vitro
characterization of human intact
erythrocytes loaded by enalaprilat. Drug
Deliv 2001;8:223-230.
39 Waitumbi JN, Malachi OO, Muga R O,
Misore AO, Stoute JA: Red cell surface
changes and erythrophagocytosis in
children with severe Plasmodium
falciparum anemia. Blood 2000;95:1481-
1486.
40 Coligan EJ, Kruisbeek MA, Margulies HD,
Shevach ME, Strober W: Current
protocols in Immunology (eds).Wiley
Interscience, National Institute of Health
1993,vol 1,pp 32-34.
41 Towbin H, Staehelin T, Gordon J:
Electrophoretic transfer of proteins from
polyacrylamide gels to nitrocellulose
sheets: procedure and some applications.
Proc Natl Acad Sci USA 1979;76:4350-
4354.
42 Hunter WM: Handbook of Experimental
Medicine. Blackwell Scientific
Publication (Weir, D.M. edition) Oxford
1978,vol 14,pp 1-3.
43 Scatchard G: The attractions of proteins
for small molecules and ions, Ann NY
Acad Sci 1949;51:660-672.
44 Dominguez M, Moreno I, Lopez-
Trascasa M, Torano MA: Complement
interaction with trypanosomatid
promastigotes in normal human serum. J
Exp Med 2002;195:451-459.
45 van Dam AP, Hack CE: Formation of
C3-IgG complexes in serum by aggregated
IgG and by non-immunoglobulin
activators of complement. Immunology
1987;61:105-110.
46 Bandyopadhyay S, Chatterjee M, Das T,
Bandyopadhyay S, Sundar S, Mandal C:
Antibodies directed against O-acetylated
sialoglycoconjugates accelerate
complement activation in Leishmania
donovani promastigotes. J Infect Dis
2004;190:2010-2019.
47 Bandyopadhyay S, Bhattacharya A,
Mallick A, Sen AK, Tripathi G, Das T,
Ghosh S, Bhattacharya DK, Mandal C:
Over-expressed IgG2 antibodies against
O-acetylated sialoglycoconjugates
incapable of proper effector functioning
in childhood acute lymphoblastic
leukemia. Int Immunol 2005;17:177-
191.
48 Chava AK, Chatterjee M, Sharma V,
Sundar S, Mandal C: Variable degree of
alternative complement pathway-
mediated hemolysis in Indian visceral
leishmaniasis induced by differential
expression of 9-O-acetylated
sialoglycans. J Infect Dis
2004;189:1257-1264.
49 Jakobsen PH, Bate CA, Taverne J,
Playfair JH: Malaria: toxins, cytokines
and disease. Parasite Immunol
1995;17:223-231.
50 Gabay C, Kushner I: Acute-phase proteins
and other systemic responses to
inflammation. N Engl J Med.
1999;340:448-54.
51 Hack EC, Wolbink GJ, Schalkwijk C,
Speijer H, Hermens WT, van den Bosch
H: A role for secretory phospholipase
A2 and C-reactive protein in the removal
of injured cells. Immunol Today
1997;18:111–115.
52 Volanakis JE, Wirtz KW: Interaction of
C-reactive protein with artificial
phosphatidylcholine bilayers. Nature
1979;281:155-157.
53 Gould JM, Weiser JN: Expression of C-
reactive protein in the human
respiratory tract. Infect Immun
2001;69:1747-175.
54 Pied S, Nussler A, Pontent M, Miltgen F,
Matile H, Lambert PH, Mazier D: C-
reactive protein protects against
preerythrocytic stages of malaria. Infect
Immun 1989;57:278-282.
55 Kottgen E, Hell B, Kage A, Tauber R:
Lectin specificity and binding
characteristics of human C-reactive
protein. J Immunol 1992;149:445-453.
56 J Brzeszczynska, K Gwozdzinski:
Erythrocyte membrane damage induced
by t –butylhydroperoxide. Curr Top
Biophys 1998;22:27-32.
57 Frank MM: The role of macrophages in
bloodstream clearance; In Human
Monocytes: Zembala M, Asherson GL
(eds): Academic, London 2002,vol
pp.337.
58 Lutz HU: Innate immune and non-
immune mediators of erythrocyte
clearance. Cell Mol Biol (Noisy-le-grand)
2004;50:107-116.
59 Lang KS, Lang PA, Bauer C, Duranton
C, Wieder T, Huber SM, Lang F:
Mechanisms of suicidal erythrocyte
death. Cell Physiol Biochem
2005;15:195-202.
60 Ross GD, Yount WJ, Walport MJ,
Winfield JB, Parker CJ, Fuller CR, Taylor
RP, Myones BL, Lachmann PJ: Disease-
associated loss of erythrocyte
complement receptors (CR1, C3b
Receptors) in patients with systemic
lupus erythematosus and other diseases
involving autoantibodies and/or
complement activation. J Immunol
1985;135:2005–2014.
61 Adam C, Geniteau M, Gougerot-Pocidalo
M, Verroust P, Lebras J, Gibert C, Morel-
Maroger L: Cryoglobulins, circulating
immune complexes, and complement
activation in cerebral malaria. Infect
Immun 1981; 31:530-535.
62 Gehrs BC, Friedberg RC: Autoimmune
hemolytic anemia. Am J Hematol
2002;69:258-271.
63 Saxena RK: Should erythrocyte
destruction in vivo be through
phagocytosis alone? J Biosci 2000;25:3-
5.
64 Stoute JA: Complement-regulatory
proteins in severe malaria: too little or
too much of a good thing? Trends
Parasitol 2005 21:218-223.
65 Devine DV: The regulation of
complement on cell surfaces. Transfus
Med Rev 1991;5:123–31.
Ansar/Habib/Roy/Mandal/MandalCell Physiol Biochem 2009;23:175-190
